Thiopurines in inflammatory bowel disease: New strategies for optimization of pharmacotherapy?
- Cite this article as:
- Derijks, L.J.J. & Hommes, D.W. Curr Gastroenterol Rep (2006) 8: 89. doi:10.1007/s11894-006-0001-0
New strategies for optimizing thiopurine therapy of IBD are promising. TDM and TPMT genotyping seem to be important tools for fine tuning thiopurine therapy, thereby reducing toxicity and improving efficacy. ITPA genotyping and the use of 6-TG in IBD need further research before they can be advocated or banned.
Unable to display preview. Download preview PDF.